| 1 |
2023 |
Jesse Lopes da Silva, Giselle de Souza Carvalho, Lucas Zanetti de Albuquerque, Fabiana Resende Rodrigues, Priscila Valverde Fernandes, Daniel Kischinhevsky, Andreia Cristina de Melo. Exploring Real-World HER2-Low Data in Early-Stage Triple-Negative Breast Cancer: Insights and Implications, Breast Cancer: Targets and Therapy. 2023; Volume 15: 337.
https://doi.org/10.2147/BCTT.S408743 |
| 2 |
2023 |
Joshua Hurwitz, Lucy Roxana Haggstrom, Elgene Lim. Antibody–Drug Conjugates: Ushering in a New Era of Cancer Therapy, Pharmaceutics. 2023; 15: 2017.
https://doi.org/10.3390/pharmaceutics15082017 |
| 3 |
2022 |
Ciaran Devoy, Yensi Flores Bueso, Mark Tangney. Understanding and harnessing triple-negative breast cancer-related microbiota in oncology, Frontiers in Oncology. 2022; 12: 1020121.
https://doi.org/10.3389/fonc.2022.1020121 |
| 4 |
2023 |
Md Abdus Subhan, Vladimir P. Torchilin. Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate, Pharmaceutics. 2023; 15: 1242.
https://doi.org/10.3390/pharmaceutics15041242 |
| 5 |
2023 |
Duygu Akca, Adrian Simon, Reinhard Buettner, Christiane Bruns, Wolfgang Schroeder, Thomas Zander, Florian Gebauer, Alexander Quaas. Syndecan‑1 expression is an independent favourable prognostic marker in oesophageal adenocarcinoma and represents a potential therapeutic target, Oncology Letters. 2023; 26: 356.
https://doi.org/10.3892/ol.2023.13942 |
| 6 |
2022 |
Yueyang Liu, Weiwei Gong, Sarah Preis, Julia Dorn, Marion Kiechle, Ute Reuning, Viktor Magdolen, Tobias F. Dreyer. A Pair of Prognostic Biomarkers in Triple-Negative Breast Cancer: KLK10 and KLK11 mRNA Expression, Life. 2022; 12: 1517.
https://doi.org/10.3390/life12101517 |
| 7 |
2022 |
Desh Deepak Singh, Hae-Jeung Lee, Dharmendra Kumar Yadav. Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer, Frontiers in Pharmacology. 2022; 13: 1089066.
https://doi.org/10.3389/fphar.2022.1089066 |
